PRA Health Sciences’ Q2 revenue is up 35%, as the CRO accelerates integration plans with Symphony Health and predicts an increase in staff towards the end of the year.
Modeling and simulation can provide “meaningful prediction” of a drug’s pharmacodynamic range and maximum dose – the use of which might have prevented the tragic outcome of the BIAL 10-2474 trial in 2016, says Certara VP.
Revenue growth has taken off, driven by steady start-up on several programs, as the CRO remains focused on its core market of small and midsized biopharma – which makes up the majority of its revenue.
Robotics and automation will help improve the clunky and expensive clinical trial process, says Icon CEO – as the company continues to evaluate potential opportunities to improve efficiency.
Outsourcing-Pharma recently conducted a second ‘state of the industry’ survey to gauge views about the current state of the global pharmaceutical outsourcing market and the evolving relationships of those involved.
TransCelerate and BioCelerate have launched a new data sharing platform to connect preclinical and clinical information to help better inform clinical trials.
LabCorp signed several partnership deals in the second quarter of 2018 as the company aims to enhance the drug development process and continues to invest in its CRO business.
Iqvia recently announced its second quarter 2018 results, which came in “above the high end” of the company’s expectations at $2.567bn, said CEO Ari Bousbib.
Repeal of the hotly debated medical device tax would free up research and development resources and bring clinical trials back to the US, say CRO industry executives.
